Adma Biologics Cmn (ADMA) 6.79 $ADMA
ADMA Biologics to Present at the 2016 JMP Securities Life Sciences Conference
GlobeNewswire - Thu Jun 16, 6:38AM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the 2016 JMP Securities Life Sciences Conference on June 21, 2016 at The St. Regis New York.
ADMA: 6.79 (-0.05)
Adma Biologics reports 1Q loss
Automated Insights - Fri May 13, 4:16PM CDT
RAMSEY, N.J. (AP) _ Adma Biologics Inc. (ADMA) on Friday reported a loss of $4.6 million in its first quarter.
ADMA: 6.79 (-0.05)
ADMA Biologics Reports First Quarter 2016 Results
GlobeNewswire - Fri May 13, 4:05PM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the quarter ended March 31, 2016, and recent accomplishments and anticipated milestones for 2016.
ADMA: 6.79 (-0.05)
ADMA Biologics Further Enhances Cash Position by Securing $4.0 Million in Additional Capital Through Amended Loan and Security Agreement with Oxford Finance
GlobeNewswire - Fri May 13, 3:05PM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has accessed an additional $4.0 million from its lender, Oxford Finance LLC (Oxford), made available through an amendment of the parties' existing loan and security agreement. The amendment provides ADMA with the option to draw an additional $5 million upon the approval for its Biologics License Application (BLA) for RI-002 from the U.S. Food and Drug Administration (FDA) on or before January 31, 2017. If ADMA exercises this option, it will be able to extend the expiration of the interest only period from January 31, 2017 to July 31, 2017.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue May 03, 9:47AM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 1,892,308 shares of its common stock at a public offering price of $6.50 per share, as well as 283,846 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. The gross proceeds from the offering, including the underwriters' over-allotment option exercise, are approximately $14.1 million.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Apr 28, 8:16AM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 1,892,308 shares of common stock at a public offering price of $6.50 per share, resulting in gross proceeds of approximately $12.3 million. Members of management and the Board of Directors participated in excess of ten percent in the offering.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Apr 27, 3:06PM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Data on RI-002 to be Presented at the Clinical Immunology Society 2016 Annual Meeting
GlobeNewswire - Tue Apr 12, 6:38AM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that a poster titled "Protective Levels of Neutralizing Antibodies to Influenza are Present in an IVIG (RI-002) Containing Standardized and Elevated Levels of Neutralizing Antibodies to RSV and Can Protect Influenza Infected Cotton Rats," will be presented at the Clinical Immunology Society 2016 Annual Meeting, being held April 14-17, 2016, in Boston, Massachusetts.
ADMA: 6.79 (-0.05)
ADMA Biologics Reports Year End 2015 Financial Results, Accomplishments and Upcoming Milestones
GlobeNewswire - Wed Mar 23, 3:26PM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2015, and outlined the company's 2015 accomplishments and anticipated milestones for 2016.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Data Presented at 2016 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI)
GlobeNewswire - Mon Mar 07, 6:38AM CST
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its abstract titled "A High Titer Anti-RSV Polyclonal Antibody (RI-002) Prevents Infection with Palivizumab Resistant RSV in Cotton Rats and Achieves Greater Neutralizing Anti-RSV Activity as Compared to Palivizumab" was presented as a poster session at the 2016 American Academy of Allergy Asthma & Immunology (AAAAI), annual meeting, being held March 4-8, 2016 in Los Angeles, California.
ADMA: 6.79 (-0.05)
Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5krjz7/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Respiratory Syncytial Virus (RSV) Infections Overview - Therapeutics Development - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - Folia Biotech Inc. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Globavir Biosciences, Inc. - Humabs BioMed SA - iBio, Inc. - ILiAD Biotechnologies, LLC - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Romark Laboratories, L.C. - Sirnaomics, Inc. - Spider Biotech - Spring Bank Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - The International Biotechnology Center (IBC) Generium - Vaxart, Inc. - VBI Vaccines Inc. For more information visit http://www.researchandmarkets.com/research/5k...espiratory
ADMA: 6.79 (-0.05), EBS: 33.44 (+0.20), BOTA: 1.55 (-0.04), VBIV: 3.50 (-0.10), GSK: 44.16 (+0.12), GILD: 81.05 (-7.50), MRK: 58.36 (-0.20), IBIO: 0.62 (-0.01)
Primary Immune Deficiency (PID) - Pipeline Review 2015
M2 - Wed Jan 06, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/d3x678/primary_immune) has announced the addition of the "Primary Immune Deficiency (PID) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Immune Deficiency (PID), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Primary Immune Deficiency (PID). - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - ADMA Biologics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Genethon - GlaxoSmithKline Plc - Green Cross Corporation - Octapharma AG - ProMetic Life Sciences Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/d3...ary_immune
BLCM: 14.86 (+0.35), ADMA: 6.79 (-0.05), SGMO: 5.83 (+0.07), GSK: 44.16 (+0.12), BXLT: 46.02 (-0.18)
ADMA Biologics Expands Commercial Operations Team in Preparation for Commercial Launch of RI-002 in Second Half of 2016
GlobeNewswire - Wed Dec 09, 6:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), announced today the expansion of its commercial operations team, appointing Alan Erck as the Company's Vice President, Sales and National Accounts. ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases.
ADMA: 6.79 (-0.05)
ADMA Biologics to Present at the Oppenheimer 26th Annual Healthcare Conference
GlobeNewswire - Thu Dec 03, 7:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the Oppenheimer 26 Annual Healthcare Conference at 11:30 AM ET on December 9, 2015 at the Westin Grand Central Hotel in New York City.
ADMA: 6.79 (-0.05)
ADMA Biologics Reports Third Quarter 2015 Results
GlobeNewswire - Tue Nov 10, 3:53PM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the third quarter ended September 30, 2015 and provided a corporate update and anticipated upcoming milestones.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Data to be Presented at the International Primary Immunodeficiencies Congress in Budapest Hungary
GlobeNewswire - Tue Nov 03, 6:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that a poster for its IVIG product (RI-002) entitled "Protection Against Palivizumab Resistant RSV with an IVIG Containing High Titer Anti RSV Neutralizing Antibodies," will be presented at the upcoming 2nd International Primary Immunodeficiencies Congress, being held November 5-6, 2015 in Budapest, Hungary.
ADMA: 6.79 (-0.05)
ADMA Biologics Receives Milestone Payment From Biotest AG for RI-002 BLA Submission to FDA
GlobeNewswire - Wed Sep 30, 6:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced it has received a milestone payment from Biotest Aktiengesellschaft (Biotest AG) as a result of the filing of its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), in accordance with the license agreement entered into on December 31, 2012.
ADMA: 6.79 (-0.05)
ADMA Biologics Recognized as One of the 50 Fastest Growing Companies in New Jersey
GlobeNewswire - Mon Sep 28, 6:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that the Company has been recognized as one of the 50 fastest growing companies in New Jersey by NJBIZ, a leading New Jersey-focused weekly business new publication.
ADMA: 6.79 (-0.05)
ADMA Biologics to Present at the Ladenburg Thalmann 2015 Healthcare Conference
GlobeNewswire - Tue Sep 22, 7:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015 in New York City at the Sofitel New York.
ADMA: 6.79 (-0.05)
ADMA Biologics to Present at the 2016 JMP Securities Life Sciences Conference
GlobeNewswire - Thu Jun 16, 6:38AM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the 2016 JMP Securities Life Sciences Conference on June 21, 2016 at The St. Regis New York.
ADMA: 6.79 (-0.05)
Adma Biologics reports 1Q loss
Automated Insights - Fri May 13, 4:16PM CDT
RAMSEY, N.J. (AP) _ Adma Biologics Inc. (ADMA) on Friday reported a loss of $4.6 million in its first quarter.
ADMA: 6.79 (-0.05)
ADMA Biologics Reports First Quarter 2016 Results
GlobeNewswire - Fri May 13, 4:05PM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the quarter ended March 31, 2016, and recent accomplishments and anticipated milestones for 2016.
ADMA: 6.79 (-0.05)
ADMA Biologics Further Enhances Cash Position by Securing $4.0 Million in Additional Capital Through Amended Loan and Security Agreement with Oxford Finance
GlobeNewswire - Fri May 13, 3:05PM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has accessed an additional $4.0 million from its lender, Oxford Finance LLC (Oxford), made available through an amendment of the parties' existing loan and security agreement. The amendment provides ADMA with the option to draw an additional $5 million upon the approval for its Biologics License Application (BLA) for RI-002 from the U.S. Food and Drug Administration (FDA) on or before January 31, 2017. If ADMA exercises this option, it will be able to extend the expiration of the interest only period from January 31, 2017 to July 31, 2017.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue May 03, 9:47AM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 1,892,308 shares of its common stock at a public offering price of $6.50 per share, as well as 283,846 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. The gross proceeds from the offering, including the underwriters' over-allotment option exercise, are approximately $14.1 million.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Apr 28, 8:16AM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 1,892,308 shares of common stock at a public offering price of $6.50 per share, resulting in gross proceeds of approximately $12.3 million. Members of management and the Board of Directors participated in excess of ten percent in the offering.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Apr 27, 3:06PM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Data on RI-002 to be Presented at the Clinical Immunology Society 2016 Annual Meeting
GlobeNewswire - Tue Apr 12, 6:38AM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that a poster titled "Protective Levels of Neutralizing Antibodies to Influenza are Present in an IVIG (RI-002) Containing Standardized and Elevated Levels of Neutralizing Antibodies to RSV and Can Protect Influenza Infected Cotton Rats," will be presented at the Clinical Immunology Society 2016 Annual Meeting, being held April 14-17, 2016, in Boston, Massachusetts.
ADMA: 6.79 (-0.05)
ADMA Biologics Reports Year End 2015 Financial Results, Accomplishments and Upcoming Milestones
GlobeNewswire - Wed Mar 23, 3:26PM CDT
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2015, and outlined the company's 2015 accomplishments and anticipated milestones for 2016.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Data Presented at 2016 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI)
GlobeNewswire - Mon Mar 07, 6:38AM CST
ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its abstract titled "A High Titer Anti-RSV Polyclonal Antibody (RI-002) Prevents Infection with Palivizumab Resistant RSV in Cotton Rats and Achieves Greater Neutralizing Anti-RSV Activity as Compared to Palivizumab" was presented as a poster session at the 2016 American Academy of Allergy Asthma & Immunology (AAAAI), annual meeting, being held March 4-8, 2016 in Los Angeles, California.
ADMA: 6.79 (-0.05)
Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5krjz7/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Respiratory Syncytial Virus (RSV) Infections Overview - Therapeutics Development - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview - Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies - Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes - Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - Folia Biotech Inc. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Globavir Biosciences, Inc. - Humabs BioMed SA - iBio, Inc. - ILiAD Biotechnologies, LLC - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Romark Laboratories, L.C. - Sirnaomics, Inc. - Spider Biotech - Spring Bank Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - The International Biotechnology Center (IBC) Generium - Vaxart, Inc. - VBI Vaccines Inc. For more information visit http://www.researchandmarkets.com/research/5k...espiratory
ADMA: 6.79 (-0.05), EBS: 33.44 (+0.20), BOTA: 1.55 (-0.04), VBIV: 3.50 (-0.10), GSK: 44.16 (+0.12), GILD: 81.05 (-7.50), MRK: 58.36 (-0.20), IBIO: 0.62 (-0.01)
Primary Immune Deficiency (PID) - Pipeline Review 2015
M2 - Wed Jan 06, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/d3x678/primary_immune) has announced the addition of the "Primary Immune Deficiency (PID) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Immune Deficiency (PID), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Primary Immune Deficiency (PID). - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - ADMA Biologics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Genethon - GlaxoSmithKline Plc - Green Cross Corporation - Octapharma AG - ProMetic Life Sciences Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/d3...ary_immune
BLCM: 14.86 (+0.35), ADMA: 6.79 (-0.05), SGMO: 5.83 (+0.07), GSK: 44.16 (+0.12), BXLT: 46.02 (-0.18)
ADMA Biologics Expands Commercial Operations Team in Preparation for Commercial Launch of RI-002 in Second Half of 2016
GlobeNewswire - Wed Dec 09, 6:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), announced today the expansion of its commercial operations team, appointing Alan Erck as the Company's Vice President, Sales and National Accounts. ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases.
ADMA: 6.79 (-0.05)
ADMA Biologics to Present at the Oppenheimer 26th Annual Healthcare Conference
GlobeNewswire - Thu Dec 03, 7:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the Oppenheimer 26 Annual Healthcare Conference at 11:30 AM ET on December 9, 2015 at the Westin Grand Central Hotel in New York City.
ADMA: 6.79 (-0.05)
ADMA Biologics Reports Third Quarter 2015 Results
GlobeNewswire - Tue Nov 10, 3:53PM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the third quarter ended September 30, 2015 and provided a corporate update and anticipated upcoming milestones.
ADMA: 6.79 (-0.05)
ADMA Biologics Announces Data to be Presented at the International Primary Immunodeficiencies Congress in Budapest Hungary
GlobeNewswire - Tue Nov 03, 6:38AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that a poster for its IVIG product (RI-002) entitled "Protection Against Palivizumab Resistant RSV with an IVIG Containing High Titer Anti RSV Neutralizing Antibodies," will be presented at the upcoming 2nd International Primary Immunodeficiencies Congress, being held November 5-6, 2015 in Budapest, Hungary.
ADMA: 6.79 (-0.05)
ADMA Biologics Receives Milestone Payment From Biotest AG for RI-002 BLA Submission to FDA
GlobeNewswire - Wed Sep 30, 6:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced it has received a milestone payment from Biotest Aktiengesellschaft (Biotest AG) as a result of the filing of its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), in accordance with the license agreement entered into on December 31, 2012.
ADMA: 6.79 (-0.05)
ADMA Biologics Recognized as One of the 50 Fastest Growing Companies in New Jersey
GlobeNewswire - Mon Sep 28, 6:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that the Company has been recognized as one of the 50 fastest growing companies in New Jersey by NJBIZ, a leading New Jersey-focused weekly business new publication.
ADMA: 6.79 (-0.05)
ADMA Biologics to Present at the Ladenburg Thalmann 2015 Healthcare Conference
GlobeNewswire - Tue Sep 22, 7:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015 in New York City at the Sofitel New York.
ADMA: 6.79 (-0.05)
